--- title: "Thymolin" canonical_url: https://bestpeptidecalculator.app/library/thymolin description: "Vendor thymic-immune peptide listing; identity may overlap thymulin/thymogen/thymalin depending on supplier. Not FDA-approved." updated: 2026-11-07 publisher: Peptide Library notice: "Research and educational use only. Not medical advice." --- # Thymolin Thymolin (also called Thymic peptide complex) is a thymic peptide. Thymolin is marketed as a thymic immunomodulator, but the name is not an international nonproprietary name and does not map to one defined molecule; material sold under it may be a thymic extract, a synthetic fragment, or a preparation closely related to Thymalin. Vendor thymic-immune peptide listing; identity may overlap thymulin/thymogen/thymalin depending on supplier. Not FDA-approved. Also known as: Thymic peptide complex. Categories: Experimental. ## Classification - Type: Thymic peptide / research - Mechanism class: Thymic Peptide - Development stage: Research only - Regulatory class: Research compound, not FDA-approved ## Mechanism Thymolin is marketed as a thymic immunomodulator, but the name is not an international nonproprietary name and does not map to one defined molecule; material sold under it may be a thymic extract, a synthetic fragment, or a preparation closely related to Thymalin. That ambiguity is the most important thing a reference can say about it, and the certificate of analysis should be checked to establish what a given product actually contains. Where the material is a thymic peptide preparation, the proposed activity is support of T-cell differentiation and maturation analogous to endogenous thymic hormones. There is no controlled human efficacy evidence for the named product. Targets: Thymic immune signaling (claimed). Origin: Commercial thymic peptide label. ## Properties - Half-life: Not established ## Evidence - Evidence level: Insufficient Evidence - Highest documented: None documented - Human trials: 0 - Controlled human trials: 0 - Preclinical sources: 0 No human dose is established for this compound. Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess. ### Studies 1. Thymalin in the combined treatment of parkinsonism patients. Lik Sprava. 1999. 1999. Human study (early or uncontrolled). Population: Patients aged 45–72 with stage 1.5–2.5 idiopathic parkinsonism (n=15). The author reports better well-being and parkinsonian symptoms, and EEG changes, after a course of treatment. Research on a related compound, not this one. Limitations: Studied an analog, not Thymolin itself [Source](https://pubmed.ncbi.nlm.nih.gov/10424021/) 2. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003. 2003. Human study (early or uncontrolled). Population: Elderly and older adults (n=266, including epithalamin and combined groups). The authors report fewer acute respiratory illnesses and lower mortality than controls. Research on a related compound, not this one. Limitations: Studied an analog, not Thymolin itself [Source](https://pubmed.ncbi.nlm.nih.gov/14523363/) ## Safety Side effects: Unknown / product-dependent. Risks: Ambiguous identity. Human safety basis: No controlled human safety data Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use.. ## Regulatory status Thymolin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use. - FDA status: Not Approved - Availability: Research-Only ## Frequently asked questions ### What is Thymolin? Vendor thymic-immune peptide listing; identity may overlap thymulin/thymogen/thymalin depending on supplier. Not FDA-approved. ### How does Thymolin work? Thymolin is marketed as a thymic immunomodulator, but the name is not an international nonproprietary name and does not map to one defined molecule; material sold under it may be a thymic extract, a synthetic fragment, or a preparation closely related to Thymalin. That ambiguity is the most important thing a reference can say about it, and the certificate of analysis should be checked to establish what a given product actually contains. ### Is Thymolin FDA approved? No. Thymolin is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. ### What peptides are similar to Thymolin? Compounds most often compared with Thymolin include Thymosin Alpha-1, Thymalin, Thymogen (Oglufanide) and Thymopentin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ. ## References - [\[Thymalin in the combined treatment of parkinsonism patients\] — Lik Sprava, 1999](https://pubmed.ncbi.nlm.nih.gov/10424021/) - [Class-level evidence — Histiocytosis-X — N Engl J Med, 1981](https://pubmed.ncbi.nlm.nih.gov/6449667/) - [Class-level evidence — Peptides and Ageing — Neuro Endocrinol Lett, 2002](https://pubmed.ncbi.nlm.nih.gov/12374906/) - [Class-level evidence — Analogues in immunology — Ric Clin Lab, 1984](https://pubmed.ncbi.nlm.nih.gov/6091238/) - [Class-level evidence — Precursors of thymic peptides as stress sensors — Expert Opin Biol Ther, 2020](https://pubmed.ncbi.nlm.nih.gov/32700610/)